Htg Molecular Diagnostics, Inc. · OTC:HTGMQ
Htg Molecular Diagnostics — Investor Presentation (January 2021)
24 slides from Htg Molecular Diagnostics's investor presentation, Jan 6, 2021
Slide 1: Advancing the Promise of Precision Medicine: Corporate Overview
Advancing the Promise of Precision Medicine Corporate Overview January 2021 Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our transactions with biopharmaceutical compani
Slide 3: Enabling precision medicine with gene expression profiling in three market segments
Enabling precision medicine with gene expression profiling in three market segments 3 Translational profiling Clinical diagnostics Drug development NGS GEP publications have doubled to >10K annually over the last 5 years, immuno-oncology is a major driver Leading biopharma customers using RNA biomar
Slide 4: COVID impacted growth timeline but market drivers remain
COVID impacted growth timeline but market drivers remain 4 HTG revenue growth $10M $30M $20M 2016 2017 2015 $8.0M $6.8M $12.4M $21.5M 2019 $9.1M 2018 $4.6M $14.6M $14.8M $19.2M Notes: * Direct revenue include all products and services provided by HTG directly, does not include partnered collaboratio
Slide 5: Target markets are large and fast growing
Target markets are large and fast growing 5 Oncology clinical trials leveraging GEP 3.1K 9% 2014 13% 2015 10% 15% 2016 2017 2019 18% 2018 20% 2.4K 2.7K 2.9K 3.3K 3.4K 7% 25% 3% NGS GEP tools supplier market* CAGR 2020 2015 $0.52B 2025F $1.00B $1.96B ~15% CAGR Translational profiling BioPharma Servic
Slide 6: Clinical diagnostics market
Clinical diagnostics market 6 + Source – Cancer.gov, OECI.eu
Slide 7: Gene expression profiling is a cornerstone biomarker for precision medicine
Gene expression profiling (GEP) is a cornerstone biomarker for precision medicine 7 RNA GEP measures aberrations in the abundance of gene transcripts to drive precision medicine DNA GEP complements mutation information that is only part of the puzzle for precision medicine Protein GEP advantaged ove
Slide 8: HTG's EdgeSeq designed to redefine RNA-seq for GEP
HTG’s EdgeSeq designed to redefine RNA-seq for GEP 8 Traditional RNA-seq Great for mutation detection, inefficient for RNA GEP EdgeSeq Purpose-built for high-performance GEP
Slide 9: Hybrid commercial strategy – products and services
Hybrid commercial strategy – products and services 9 HTG EdgeSeq target enrichment Hybrid commercial strategy Biopharma services Instruments & kits
Slide 10: Translational profiling
Translational profiling ‘Translational profiling BioPharma Services Clinical diagnostics
Slide 11: Targeted panels drive HTG's translational profiling
Targeted panels drive HTG’s translational profiling 11 HTG EdgeSeq™ Immune Response Panel 2,003 genes to assess a variety of autoimmune diseases HTG EdgeSeq™ miRNA Whole-Transcriptome Assay 2,083 human miRNA - analysis using a variety of samples HTG EdgeSeq™ Mouse mRNA Tumor Panel 1,659 mRNA targets
Slide 12: HTG's Reveal software simplifies bioinformatics
HTG’s Reveal software simplifies bioinformatics 12 Web-based statistical analysis packages Visualizes complex gene expression profiles All sessions are encrypted and protected to preserve privacy and integrity of data All analyses and outputs can be saved and archived locally
Slide 13: Reveal applications – one assay with many applications
Reveal applications – like a smartphone, one assay with many applications 13 HTG EdgeSeq Precision Immuno-Oncology Panel HTG Assay HTG Apps 1 Slide
Slide 14: BioPharma services
BioPharma services ‘Translational profiling BioPharma Services Clinical diagnostics
Slide 15: Biopharma services strategy
Biopharma services Strategy Become the platform technology of choice for RNA GEP biomarker development Leverage that into pharma collaborations for CDx opportunities Collaborations are pharma sponsored ‘shots on goal’ for a clinical app 15 44 Active Biopharma Programs – December 31, 2020 Net decline
Slide 16: Market drivers remain in place for Biopharma services
Market drivers remain in place for Biopharma services 16 Notes: * Only oncology (hematological and solid tumors) interventional trials measuring at least one drug (devices and surgery excluded), all sponsor types, with and without RNA / Gene expression biomarkers Source: Amplion; Contract Consultant
Slide 17: Clinical diagnostics
‘Translational profiling BioPharma Services Clinical diagnostics
Slide 18: WTTx – the next step for HTG
WTTx – the next step for HTG Enable a global system biology view with EdgeSeq benefits 18 WTTx – whole transcriptome, 20k+ genes Targeted panels – 1 – 3k genes
Slide 19: Opportunities for WTTx
Opportunities for WTTx 19 WTTX is intended to uniquely enable NGS GEP CDx, RNA-seq is seen as not clinically deployable HTG’s instruments and kits enable a distributed model HTG’s QIAGEN Distribution Agreement facilitates global market access options Enables NGS GEP diagnostics in a centralized CLIA
Slide 20: WTTx transcriptome: technical feasibility milestone, October 2020
WTTx transcriptome: Critical milestone achievement – technical feasibility, October 2020 20 The relationship between signal and abundance for ERCC spike-in controls. The log2-transformed signal for the ERCC transcripts are plotted on the y-axis vs ERCC spike-in amount on the x-axis. The Pearson corr
Slide 21: January update – technical feasibility results
January update – technical feasibility results 21 Conclusion: Melanoma, breast, lung, and colorectal cancer tissue samples were run in triplicate. Pearson correlation coefficients between individual replicates ranged from 0.90 to 0.95 indicating high level of reproducibility. Conclusion: Principal C
Slide 22: 2021 HTG WTTx development milestones
22 2021 HTG WTTx development milestones Q1 2021 Q2 2021 Q3 2021 Q4 2021 White paper 2 Design lock Initial product launch Sample type expansion Milestones Q12020 Q2 2020 Q3 2020 Q4 2020
Slide 23: Target Customer Segments
Target Customer Segments 23 Translational profiling Clinical diagnostics Drug development Investigators using gene expression data in oncology, immune response, transplant and other disease areas Leading biopharma using gene expression to develop precision medicines MDx companies and CLIA laboratori
Slide 24: Key Growth Strategies
24 New targeted panel apps Extend utility of existing panels with turnkey apps for biopharma Roadmap set for sequential launches throughout 2021 Transcriptome solution Expand EdgeSeq market reach with WTTx as a universal platform for biopharma & dx development Development progress on track for launc
HTG Molecular Diagnostics — Investor Presentation (January 2021) on 6ix